chidamide + cyclophosphamide + prednisone + thalidomide

C-CPT, commonly termed the **CPCT regimen**, is an investigational all-oral co-administration regimen for fragile patients with relapsed or refractory peripheral T-cell lymphoma who cannot tolerate standard chemotherapy. It combines the selective histone deacetylase inhibitor chidamide with low-dose metronomic cyclophosphamide, prednisone, and thalidomide, followed by chidamide maintenance after induction. In the registered multicenter Phase II study NCT02879526, the regimen used chidamide 30 mg twice weekly, cyclophosphamide 50 mg daily, prednisone 20 mg daily, and thalidomide 100 mg daily. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02879526))

Other names

C-CPTC-PCTCPCTchidamide + cyclophosphamide + prednisone + thalidomidechidamide + prednisone + cyclophosphamide + thalidomide